Supernus raises $350M in convertible senior notes
Neurology company Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) raised $350 million through the sale of 0.625% convertible senior notes due 2023. The notes have an initial conversion price of about $59.33. The price is a 32% premium to Supernus' close of $44.90 on March 13, when it proposed the offering after market close.
Supernus gained $0.02 to $43.17 on Thursday.
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
Purchase this article for limited one-time distribution and website posting
$750 USD
